医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Gizmo Medical Announces New Manufacturing Facility in Shandong, China

2013年07月31日 AM06:10
このエントリーをはてなブックマークに追加


 

HOFFMAN ESTATES, Ill.

Gizmo Medical, LLC, a manufacturer of high quality orthopedic surgical instrumentation, announced today the opening of its new facility in Shandong, China. With state-of-the-art manufacturing equipment and a prototype shop, Gizmo Medical produces over 3,500 unique surgical instruments annually. The new facility offers expanded capabilities in electrical discharge machining (EDM) and computer numerical control (CNC) vertical milling and turning.

“This facility will further strengthen our development process of precision instruments specific to orthopedics as well as maintain our competitive position within the price sensitive international markets,” said Michael S. Butler, Principal, Gizmo Medical.

About Gizmo Medical, LLC

Gizmo Medical, LLC is a FDA registered medical OEM specializing in orthopedic surgical instrumentation. With over 10 years of engineering and manufacturing experience, Gizmo Medical offers single piece instruments (awls, probes, taps, drills) to complex assemblies (distractors, compressors, retractors, torque limiting handles).

CONTACT

Gizmo Medical, LLC
Michael S. Butler, Principal
877.65.gizmo
Info@gizmomed.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
  • MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil
  • SanBio: Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • SanBio: Supplementary Information to the Notice Regarding an Equity and Business Alliance Between Five Companies for Joint Research on the Appropriate Use, Adoption, and Stable Distribution of Regenerative Cell Medicine SB623
  • 首例神经母细胞瘤患者成功接受采用自然杀伤T细胞(CAR-NKT)的创新型CAR疗法